54  Creatinine

(mg/dL) 0.8 (0.5–1.2) 0.8 (0.6–1.6) 0.84  Total protein (g/dL) 4.7 (3.9–6.2) 4.7 (3.6–5.6) 0.15  Albumin (g/dL) 2.7 (2.2–3.5) 2.6 (1.5–3.3) 0.09 BTSA1 mouse  Total cholesterol (mg/dL) 314 (229–617) 298 (213–853) 0.52 Age and laboratory data are shown as median (interquartile range) The p values were evaluated by Fisher’s exact test for sex and Mann–Whitney U test for the others A previous study on IMN treated with a combination of PSL and CyA (2–3 mg/kg/day, twice-a-day) showed a 35 % CR ratio at the 12-month course [6]. However, there were no data for once-a-day administration. Nevertheless, the sample size (groups 1 and 2: n = 23 and n = 25, respectively) was sufficient to detect a significant difference (α = 0.05, 2-sided) on the basis of 0.8 power according to Fisher’s exact test when once-a-day administration is twice as effective (CR ratio 70 %) than twice-a-day administration. Therefore, we stopped the registration at the end of 2007. As shown in Table 3, during the treatment, 1 patient in group 1 and 2 patients in group 2 were transferred to another

hospital and could therefore I-BET151 not further participate in the study. Four patients in group 1 and 2 patients in group 2 were withdrawn because of complications and noncompliance. Finally, 18 and 21 patients in groups 1 and 2 completed the study for 48 weeks. Table 3 Withdrawn patients Group Withdrawal period (weeks) Reason Average C2 (ng/mL) Group 1 (n = 5) 9 Nausea 1042 10 Uncontrolled CyA level 1200 12 Liver dysfunction 750 12 Pneumonia 936 40 Removal   Group 2 (n = 4) 8 Brain VX-680 clinical trial tumora 693 36 Noncompliance 813 10 Removal   12 Removal   aMay not be related to CyA administration Responses in the once-a-day and twice-a-day administration groups The response around 6 months DCLK1 is important to determine the initial effect of CyA treatment as shown in RCTs and guidelines [4, 5, 15–17]. In the intention-to-treat analysis, 10 of 23 patients (43.5 %) in group 1 and 2 of 25 patients (8.0 %) in group 2 achieved CR at 24 weeks. This yielded a significant difference between groups in Fisher’s exact test (p = 0.0078). In group 1, two other patients achieved CR at 8 and 12 weeks, respectively; however, the first patient

relapsed into ICR2 by 24 weeks and the second was withdrawn thereafter because of liver dysfunction. ICR1 occurred in 1 and 10 patients in groups 1 and 2, respectively. In total, 11 (47.8 %) patients in group 1 and 12 (48.0 %) in group 2 achieved remission (CR + ICR1) (p = 1.000). Between 24 and 48 weeks, more patients achieved CR in both groups, but a few patients with CR relapsed conversely. At 48 weeks, 13 of 23 patients (56.5 %) in group 1 and 11 of 25 patients (44.0 %) in group 2 were in CR, and 14 of 23 (60.9 %) in group 1 and 16 of 25 (64.0 %) in group 2 were in CR + ICR1 (Fig. 2).